Phenazopyridine

Last updated

Phenazopyridine
Phenazopyridine.svg
Clinical data
Trade names Pyridium
AHFS/Drugs.com Monograph
MedlinePlus a682231
License data
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
Identifiers
  • 3-phenyldiazenylpyridine-2,6-diamine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.002.149 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C11H11N5
Molar mass 213.244 g·mol−1
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Phenazopyridine is a medication which, when excreted by the kidneys into the urine, has a local analgesic effect on the urinary tract. It is often used to help with the pain, irritation, or urgency caused by urinary tract infections, surgery, or injury to the urinary tract.

Contents

In 2021, it was the 285th most commonly prescribed medication in the United States, with more than 700,000 prescriptions. [1] [2]

Medical uses

Phenazopyridine is prescribed for its local analgesic effects on the urinary tract. It is sometimes used in conjunction with an antibiotic or other anti-infective medication at the beginning of treatment to help provide immediate symptomatic relief. Phenazopyridine does not treat infections or injury; it is only used for symptom relief. [3] [4] It is recommended that it be used for no longer than the first two days of antibacterial treatment as longer treatment may mask symptoms. [4]

Phenazopyridine is also prescribed for other cases requiring relief from irritation or discomfort during urination. For example, it is often prescribed after the use of an in-dwelling Foley catheter, endoscopic (cystoscopy) procedures, or after urethral, prostate, or urinary bladder surgery which may result in irritation of the epithelial lining of the urinary tract. [3]

This medication is not used to treat infection and may mask symptoms of inappropriately treated UTI. It provides symptom relief during a UTI, following surgery, or injury to the urinary tract. UTI therapy should be limited to 1–2 days. [4] Long-term use of phenazopyridine can mask symptoms. [5]

Side effects

The characteristic orange-colored urine after taking Phenazopyridine Pyridiumurine.jpg
The characteristic orange-colored urine after taking Phenazopyridine

Phenazopyridine produces a vivid color change in urine, typically to a dark orange to reddish color. This effect is common and harmless, and indeed a key indicator of the presence of the medication in the body. Users of phenazopyridine are warned not to wear contact lenses, as phenazopyridine has been known to permanently discolor contact lenses and fabrics. [3] [6] It also tends to leave an orange-yellow stain on surfaces it comes in contact with. Some may be mistakenly concerned that this indicated blood in the urine.

Phenazopyridine can also cause headaches, upset stomach (especially when not taken with food), or dizziness. Less frequently it can cause a pigment change in the skin or eyes, to a noticeable yellowish color. This is due to a depressed excretion via the kidneys causing a buildup of the medication in the skin, and normally indicates a need to discontinue usage. [4] Other such side effects include fever, confusion, shortness of breath, skin rash, and swelling of the face, fingers, feet, or legs. [3] [4] Long-term use may cause yellowing of nails. [7]

Phenazopyridine should be avoided by people with glucose-6-phosphate dehydrogenase deficiency, [4] [8] [9] [10] because it can cause hemolysis (destruction of red blood cells) due to oxidative stress. [11] It has been reported to cause methemoglobinemia after overdose and even normal doses. [12] In at least one case the patient had pre-existing low levels of methemoglobin reductase, [13] which likely predisposed her to the condition. It has also been reported to cause sulfhemoglobinemia. [4] [14] [15] [16]

Phenazopyridine is an azo dye. [17] [18] Other azo dyes, which were previously used in textiles, printing, and plastic manufacturing, have been implicated as carcinogens that can cause bladder cancer. [19] While phenazopyridine has never been shown to cause cancer in humans, evidence from animal models suggests that it is potentially carcinogenic. [4] [20]

Pregnancy

This medication has shown no adverse events in animal models, but no human trials have been conducted. [4] It is not known if phenazopyridine is excreted in breast milk. [4]

Pharmacokinetics

The full pharmacokinetic properties of phenazopyridine have not been determined. It has mostly been studied in animal models, but they may not be very representative of humans. [21] Rat models have shown its half-life to be 7.35 hours, [22] and 40% is metabolized hepatically (by the liver). [22]

Mechanism of action

Phenazopyridine's mechanism of action is not well known, and only basic information on its interaction with the body is available. It is known that the chemical has a direct topical analgesic effect on the mucosa lining of the urinary tract. It is rapidly excreted by the kidneys directly into the urine. [21] Hydroxylation is the major form of metabolism in humans, [21] and the azo bond is usually not cleaved. [21] On the order of 65% of an oral dose will be secreted directly into the urine chemically unchanged. [4]

Brand names

In addition to its generic form, phenazopyridine is distributed under the following brand names:

Related Research Articles

<span class="mw-page-title-main">Urinary tract infection</span> Infection that affects part of the urinary tract

A urinary tract infection (UTI) is an infection that affects a part of the urinary tract. When it affects the lower urinary tract it is known as a bladder infection (cystitis) and when it affects the upper urinary tract it is known as a kidney infection (pyelonephritis). Symptoms from a lower urinary tract infection include pain with urination, frequent urination, and feeling the need to urinate despite having an empty bladder. Symptoms of a kidney infection include fever and flank pain usually in addition to the symptoms of a lower UTI. Rarely the urine may appear bloody. In the very old and the very young, symptoms may be vague or non-specific.

<span class="mw-page-title-main">Cystoscopy</span> Medical procedure; endoscopy of the urinary bladder via the urethra

Cystoscopy is endoscopy of the urinary bladder via the urethra. It is carried out with a cystoscope.

<span class="mw-page-title-main">Trimethoprim</span> Antibiotic

Trimethoprim (TMP) is an antibiotic used mainly in the treatment of bladder infections. Other uses include for middle ear infections and travelers' diarrhea. With sulfamethoxazole or dapsone it may be used for Pneumocystis pneumonia in people with HIV/AIDS. It is taken orally.

Agranulocytosis, also known as agranulosis or granulopenia, is an acute condition involving a severe and dangerous lowered white blood cell count and thus causing neutropenia in the circulating blood. It is a severe lack of one major class of infection-fighting white blood cells. People with this condition are at very high risk of serious infections due to their suppressed immune system.

<span class="mw-page-title-main">Glucose-6-phosphate dehydrogenase deficiency</span> Medical condition

Glucose-6-phosphate dehydrogenase deficiency (G6PDD), which is the most common enzyme deficiency worldwide, is an inborn error of metabolism that predisposes to red blood cell breakdown. Most of the time, those who are affected have no symptoms. Following a specific trigger, symptoms such as yellowish skin, dark urine, shortness of breath, and feeling tired may develop. Complications can include anemia and newborn jaundice. Some people never have symptoms.

<span class="mw-page-title-main">Hyperammonemia</span> Medical condition

Hyperammonemia is a metabolic disturbance characterised by an excess of ammonia in the blood. It is a dangerous condition that may lead to brain injury and death. It may be primary or secondary.

<span class="mw-page-title-main">Urinalysis</span> Array of tests performed on urine

Urinalysis, a portmanteau of the words urine and analysis, is a panel of medical tests that includes physical (macroscopic) examination of the urine, chemical evaluation using urine test strips, and microscopic examination. Macroscopic examination targets parameters such as color, clarity, odor, and specific gravity; urine test strips measure chemical properties such as pH, glucose concentration, and protein levels; and microscopy is performed to identify elements such as cells, urinary casts, crystals, and organisms.

<span class="mw-page-title-main">Hematuria</span> Medical condition

Hematuria or haematuria is defined as the presence of blood or red blood cells in the urine. "Gross hematuria" occurs when urine appears red, brown, or tea-colored due to the presence of blood. Hematuria may also be subtle and only detectable with a microscope or laboratory test. Blood that enters and mixes with the urine can come from any location within the urinary system, including the kidney, ureter, urinary bladder, urethra, and in men, the prostate. Common causes of hematuria include urinary tract infection (UTI), kidney stones, viral illness, trauma, bladder cancer, and exercise. These causes are grouped into glomerular and non-glomerular causes, depending on the involvement of the glomerulus of the kidney. But not all red urine is hematuria. Other substances such as certain medications and foods can cause urine to appear red. Menstruation in women may also cause the appearance of hematuria and may result in a positive urine dipstick test for hematuria. A urine dipstick test may also give an incorrect positive result for hematuria if there are other substances in the urine such as myoglobin, a protein excreted into urine during rhabdomyolysis. A positive urine dipstick test should be confirmed with microscopy, where hematuria is defined by three or more red blood cells per high power field. When hematuria is detected, a thorough history and physical examination with appropriate further evaluation can help determine the underlying cause.

<span class="mw-page-title-main">Nitrofurantoin</span> Antibacterial drug

Nitrofurantoin is an antibacterial medication of the nitrofuran class used to treat urinary tract infections, although it is not as effective for kidney infections. It is taken by mouth.

<span class="mw-page-title-main">Urinary retention</span> Inability to completely empty the bladder

Urinary retention is an inability to completely empty the bladder. Onset can be sudden or gradual. When of sudden onset, symptoms include an inability to urinate and lower abdominal pain. When of gradual onset, symptoms may include loss of bladder control, mild lower abdominal pain, and a weak urine stream. Those with long-term problems are at risk of urinary tract infections.

<span class="mw-page-title-main">Sulfasalazine</span> Chemical compound

Sulfasalazine, sold under the brand name Azulfidine among others, is a medication used to treat rheumatoid arthritis, ulcerative colitis, and Crohn's disease. It is considered by some to be a first-line treatment in rheumatoid arthritis. It is taken by mouth or can be administered rectally.

<i>Staphylococcus saprophyticus</i> Species of bacterium

Staphylococcus saprophyticus is a Gram-positive coccus belonging to the genus Staphylococcus. S. saprophyticus is a common cause of community-acquired urinary tract infections.

<span class="mw-page-title-main">Feline lower urinary tract disease</span> Any disorder affecting the bladder or urethra of cats

Feline lower urinary tract disease (FLUTD) is a generic category term to describe any disorder affecting the bladder or urethra of cats.

Glutathione synthetase deficiency (GSD) is a rare autosomal recessive metabolic disorder that prevents the production of glutathione. Glutathione helps prevent damage to cells by neutralizing harmful molecules generated during energy production. Glutathione also plays a role in processing medications and cancer-causing compounds (carcinogens), and building DNA, proteins, and other important cellular components.

<span class="mw-page-title-main">Overactive bladder</span> Condition where a person has a frequent need to urinate

Overactive bladder (OAB) is a common condition where there is a frequent feeling of needing to urinate to a degree that it negatively affects a person's life. The frequent need to urinate may occur during the day, at night, or both. Loss of bladder control may occur with this condition. Overactive bladder affects approximately 11% of the population and more than 40% of people with overactive bladder have incontinence. Conversely, about 40% to 70% of urinary incontinence is due to overactive bladder. Overactive bladder is not life-threatening, but most people with the condition have problems for years.

<span class="mw-page-title-main">Cephaloridine</span> Chemical compound

Cephaloridine is a first-generation semisynthetic derivative of antibiotic cephalosporin C. It is a Beta lactam antibiotic, like penicillin. Its chemical structure contains 3 cephems, 4 carboxyl groups and three pyridinium methyl groups.

Urologic diseases or conditions include urinary tract infections, kidney stones, bladder control problems, and prostate problems, among others. Some urologic conditions do not affect a person for that long and some are lifetime conditions. Kidney diseases are normally investigated and treated by nephrologists, while the specialty of urology deals with problems in the other organs. Gynecologists may deal with problems of incontinence in women.

Sickle cell nephropathy is a type of nephropathy associated with sickle cell disease which causes kidney complications as a result of sickling of red blood cells in the small blood vessels. The hypertonic and relatively hypoxic environment of the renal medulla, coupled with the slow blood flow in the vasa recta, favors sickling of red blood cells, with resultant local infarction. Functional tubule defects in patients with sickle cell disease are likely the result of partial ischemic injury to the renal tubules.

Normally, human urine color is straw-yellow. Urine color other than straw-yellow sometimes reflects an abnormality—an underlying pathological condition—in human beings.

<span class="mw-page-title-main">Antiarthritics</span> Drug class

An antiarthritic is any drug used to relieve or prevent arthritic symptoms, such as joint pain or joint stiffness. Depending on the antiarthritic drug class, it is used for managing pain, reducing inflammation or acting as an immunosuppressant. These drugs are typically given orally, topically or through administration by injection. The choice of antiarthritic medication is often determined by the nature of arthritis, the severity of symptoms as well as other factors, such as the tolerability of side effects.

References

  1. ↑ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
  2. ↑ "Phenazopyridine - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
  3. 1 2 3 4 "Pyridium Plus Tablets" (PDF). Warner Chilcott. Archived from the original (PDF) on 20 April 2014. Retrieved 15 June 2019.
  4. 1 2 3 4 5 6 7 8 9 10 11 "PYRIDIUM (phenazopyridine) tablet, film coated". DailyMed. Archived from the original on 21 April 2014. Retrieved 15 June 2019.
  5. ↑ Skirrow MB (April 1969). "Urinary tract infections". British Medical Journal. 2 (5648): 687–706. doi:10.1016/j.pop.2013.06.005. PMC   1983013 . PMID   5776230.
  6. ↑ "Phenazopyridine: MedlinePlus Drug Information". Medline plus. American Society of Health-System Pharmacists, Inc. Retrieved 15 June 2019.
  7. ↑ Amit G, Halkin A (December 1997). "Lemon-yellow nails and long-term phenazopyridine use". Annals of Internal Medicine (letter). 127 (12): 1137. doi:10.7326/0003-4819-127-12-199712150-00040. PMID   9412335. S2CID   41928972.
  8. ↑ Tishler M, Abramov A (1983). "Phenazopyridine-induced hemolytic anemia in a patient with G6PD deficiency". Acta Haematologica. 70 (3): 208–209. doi: 10.1159/000206727 . PMID   6410650.
  9. ↑ Galun E, Oren R, Glikson M, Friedlander M, Heyman A (November 1987). "Phenazopyridine-induced hemolytic anemia in G-6-PD deficiency". Drug Intelligence & Clinical Pharmacy. 21 (11): 921–922. doi:10.1177/106002808702101116. PMID   3678069. S2CID   7262697.
  10. ↑ Mercieca JE, Clarke MF, Phillips ME, Curtis JR (September 1982). "Acute hemolytic anaemia due to phenazopyridine hydrochloride in G-6-PD deficient subject". Lancet. 2 (8297): 564. doi:10.1016/s0140-6736(82)90651-1. PMID   6125724. S2CID   27340450.
  11. ↑ Frank JE (October 2005). "Diagnosis and management of G6PD deficiency". American Family Physician. 72 (7): 1277–1282. PMID   16225031. Archived from the original on 28 August 2021. Retrieved 6 July 2009.
  12. ↑ Jeffery WH, Zelicoff AP, Hardy WR (February 1982). "Acquired methemoglobinemia and hemolytic anemia after usual doses of phenazopyridine". Drug Intelligence & Clinical Pharmacy. 16 (2): 157–159. doi:10.1177/106002808201600212. PMID   7075467. S2CID   20968675.
  13. ↑ Daly JS, Hultquist DE, Rucknagel DL (August 1983). "Phenazopyridine induced methaemoglobinaemia associated with decreased activity of erythrocyte cytochrome b5 reductase". Journal of Medical Genetics. 20 (4): 307–309. doi:10.1136/jmg.20.4.307. PMC   1049126 . PMID   6620333.
  14. ↑ Halvorsen SM, Dull WL (September 1991). "Phenazopyridine-induced sulfhemoglobinemia: inadvertent rechallenge". The American Journal of Medicine. 91 (3): 315–317. doi:10.1016/0002-9343(91)90135-K. PMID   1892154.
  15. ↑ Kermani TA, Pislaru SV, Osborn TG (April 2009). "Acrocyanosis from phenazopyridine-induced sulfhemoglobinemia mistaken for Raynaud phenomenon". Journal of Clinical Rheumatology. 15 (3): 127–129. doi:10.1097/RHU.0b013e31819db6db. PMID   19300288.
  16. ↑ Gopalachar AS, Bowie VL, Bharadwaj P (June 2005). "Phenazopyridine-induced sulfhemoglobinemia". The Annals of Pharmacotherapy. 39 (6): 1128–1130. doi:10.1345/aph.1E557. PMID   15886294. S2CID   22812461.
  17. ↑ Cystitis in Females~treatment at eMedicine
  18. ↑ "Phenazopyridine Hydrochloride". The American Society of Health-System Pharmacists. Retrieved 30 June 2015.
  19. ↑ Transitional Cell Carcinoma Imaging at eMedicine
  20. ↑ "Phenazopyridine Hydrochloride" (PDF). Report on Carcinogens, Twelfth Edition (2011). National Toxicology Program. Archived from the original (PDF) on 17 February 2013. Retrieved 15 June 2019.
  21. 1 2 3 4 Thomas BH, Whitehouse LW, Solomonraj G, Paul CJ (April 1990). "Excretion of phenazopyridine and its metabolites in the urine of humans, rats, mice, and guinea pigs". Journal of Pharmaceutical Sciences. 79 (4): 321–325. doi:10.1002/jps.2600790410. PMID   2352143.
  22. 1 2 Jurima-Romet M, Thomas BH, Solomonraj G, Paul CJ, Huang H (March 1993). "Metabolism of phenazopyridine by isolated rat hepatocytes". Biopharmaceutics & Drug Disposition. 14 (2): 171–179. doi:10.1002/bdd.2510140208. PMID   8453026. S2CID   29419875.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.